Hot Features
Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company’s development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 fo... Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company’s development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome; and ATR 1086, a siRNA-based therapy targeting PLN for the treatment of PLN cardiomyopathy. It also focuses on pipeline to treat a range of genetic and cardiac diseases. The company was incorporated in 2025 and is headquartered in San Diego, California. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -1.31 | -9.87189148455 | 13.27 | 13.6 | 11.93 | 197538 | 12.57942915 | CS |
| 4 | -0.92 | -7.14285714286 | 12.88 | 14.135 | 11.93 | 194764 | 12.96666632 | CS |
| 12 | -2.51 | -17.3462335867 | 14.47 | 14.7999 | 11.93 | 387008 | 13.27002392 | CS |
| 26 | -59.65 | -83.2984220081 | 71.61 | 73.06 | 11.93 | 1352743 | 59.91029193 | CS |
| 52 | -22.07 | -64.8545401117 | 34.03 | 73.06 | 11.93 | 2640480 | 56.01131611 | CS |
| 156 | 0.76 | 6.78571428571 | 11.2 | 73.06 | 4.825 | 1717637 | 41.58630382 | CS |
| 260 | -10.49 | -46.7260579065 | 22.45 | 73.06 | 4.825 | 1301026 | 36.61193863 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.